About Zentalis

We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.

Learn More

Pipeline

Candidate NameCand
PreclinicalPre
Phase 1Ph 1
Phase 2Ph 2
Phase 3Ph 3
CollaboratorsCollab
ZN-c3: WEE1 Inhibitor
GSK - Zentera logos
GSK - Zentera logos
Monotherapy

ZN-c3: WEE1 Inhibitor

Uterine Serous Carcinoma*
Uterine Serous Carcinoma*USC*
Solid Tumors
Solid TumorsSolid Tumors
Combination

ZN-c3: WEE1 Inhibitor

Osteosarcoma (+ gemcitabine)
Osteosarcoma (+ gemcitabine)Osteosarcoma
Ovarian Cancer (+ chemo)
Ovarian Cancer (+ chemo)Ov Cancer
ZN-c5: Oral SERD
Pfizer Lille Zentera logos
Pfizer Lille Zentera logos
Monotherapy

ZN-c5: Oral SERD

Breast Cancer
Breast CancerBrst Cancer
Combination

ZN-c5: Oral SERD

Breast Cancer (+ palbociclib)
Breast Cancer (+ palbociclib)Breast Cancer (+ palbociclib)
Breast Cancer (+ abemaciclib)
Breast Cancer (+ abemaciclib)Breast Cancer (+ abemaciclib)
ZN-d5: BCL-2 Inhibitor
Zentera logo
Zentera logo
Monotherapy

ZN-d5: BCL-2 Inhibitor

AML + Non-Hodgkin’s Lymphoma
AML + Non-Hodgkin’s LymphomaAML + Non-Hodgkin’s Lymphoma
ZN-e4: EGFR
SciClone logo
SciClone logo
Monotherapy

ZN-e4: EGFR

NSCLC
NSCLCNSCLC

* Registrational trial with potential accelerated approval

Learn More

Join Zentalis